Skip to main content

Table 2 Summary of time-varying characteristics over all study visits

From: Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs

  Mean (SD) Range
CRP, mg/dl 0.48 (1.48) (0.01–12.60)
ESR, mm/h 15.14 (44.05) (1–120)
Tender joint count 0.33 (0.92) (0–6)
Swollen joint count 0.41 (1.19) (0–8)
Patient’s global assessment, VAS, mm 7.73 (14.57) (0–100)
DAS28-ESR 1.87 (0.91) (0.00–4.75)
Health Assessment Questionnaire 0.25 (0.50) (0.00–2.88)
Multi-biomarker disease activity 23.23 (10.75) (13–49)
Dose percentage (ratio of the full dosage) 0.67 (0.29) (0.00–1.00)
Relative week of visit (baseline visit is week 0) 23.81 (17.53) (0–59)
BMI, kg/m2 25.19 (3.86) (17.5–39.45)
Dose percentage change* −0.06 (0.27) (−1.0–1.00)
Previous flare indicator (year/n) 0.23 (0.42) (0.00–1.00)
  1. BMI body mass index, CRP C-reactive protein, DAS-28 Disease Activity Score 28 joints, ESR erythrocyte sedimentation rate
  2. *Current dose percentage – previous dose percentage